Arbutus Biopharma
ABUS
119 hedge funds and large institutions have $131M invested in Arbutus Biopharma in 2022 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 39 increasing their positions, 35 reducing their positions, and 20 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
11% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 35
0.3% more ownership
Funds ownership: 29.24% → 29.53% (+0.3%)
2% less funds holding
Funds holding: 122 → 119 (-3)
10% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 20
15% less capital invested
Capital invested by funds: $154M → $131M (-$23M)
18% less call options, than puts
Call options by funds: $5.7M | Put options by funds: $6.99M
Top Buyers
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$8.2M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$6.23M |
| 3 |
TSC
Two Seas Capital
Rye,
New York
|
+$4.2M |
| 4 |
BC
Brookfield Corp
Toronto,
Ontario, Canada
|
+$3.47M |
| 5 |
Goldman Sachs
New York
|
+$2.6M |
Top Sellers
| 1 |
RI
RTW Investments
New York
|
-$9.74M |
| 2 |
Millennium Management
New York
|
-$3.13M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$2.6M |
| 4 |
Two Sigma Investments
New York
|
-$2.35M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$2.02M |
ABUS Hedge Fund Activity: Q1 2022 in Review
119 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q1 2022, worth a combined $131M — down 15% from $154M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of ABUS and 18 opened new positions — a net loss of 2 holders — while 35 trimmed existing stakes and 39 added.
The largest buyer was Hudson Bay Capital Management, adding an estimated $8.2M. The largest seller was RTW Investments, exiting entirely with an estimated $9.74M sold.
- 119 institutional investors held Arbutus Biopharma (ABUS) as of Q1 2022, down from 122 in Q4 2021.
- Funds reported $131M of Arbutus Biopharma stock for Q1 2022, down 15% quarter-over-quarter.
- 18 funds opened new Arbutus Biopharma positions in Q1 2022 and 20 closed out, a net change of -2 holders.
- The largest Arbutus Biopharma buyer in Q1 2022 was Hudson Bay Capital Management, an estimated $8.2M added.
- The largest Arbutus Biopharma seller in Q1 2022 was RTW Investments, an estimated $9.74M sold.
Based on aggregated 13F filings for Q1 2022.